Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of polymorphic site in growth and differentiation factor 15 in predicting hypertensive secondary left ventricular hypertrophy

A technology of growth differentiation factors and polymorphic sites, applied in the field of medical molecular biology, can solve problems such as blood stasis, increased risk of stroke, and promotion of thrombosis, achieving high representation, improving feasibility and reliability , good sensitivity and specificity

Inactive Publication Date: 2007-08-22
FUWAI HOSPITAL OF CARDIOVASCULAR DESEASE CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that left ventricular hypertrophy can easily lead to blood stasis in the heart, easily cause arrhythmias such as atrial fibrillation, promote thrombosis, and increase the risk of ischemic stroke by 2.5 times

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of polymorphic site in growth and differentiation factor 15 in predicting hypertensive secondary left ventricular hypertrophy
  • Use of polymorphic site in growth and differentiation factor 15 in predicting hypertensive secondary left ventricular hypertrophy
  • Use of polymorphic site in growth and differentiation factor 15 in predicting hypertensive secondary left ventricular hypertrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] This study is a sub-project of investigation and research on the prevalence of left ventricular hypertrophy and related risk factors in hypertensive population in rural China. We used random cluster sampling to detect 5,421 patients with essential hypertension aged 40 to 75 from 7 natural villages in Xinyang, Henan, and performed echocardiography on 4,869 of them. From a total of 7 natural villages, we randomly selected 3, and all hypertensive patients who had undergone echocardiographic detection were included in this study, excluding all other cardiovascular diseases affecting left ventricular hypertrophy (hypertrophic cardiomyopathy, valvular heart disease, pulmonary hypertension, and coronary artery disease), resulting in a study population of 1,527 (506 men, 1021 women) patients with essential hypertension.

[0027] 1. Determination of clinical indicators:

[0028] 1. Blood pressure: measure the blood pressure of the right upper limb while sitting with a mercury s...

Embodiment 2

[0115] Example 2: A kit for predicting left ventricular hypertrophy secondary to hypertension

[0116] 1. Composition: The composition and content are as follows (50 servings), stored at -20°C:

[0117] 50 μL 10×PCR buffer (TaKaRa),

[0118] 50μL 10mmol / L dNTP mixture (TaKaRa),

[0119] 12 μL (5U / uL) Taq DNA polymerase (TaKaRa),

[0120] Each 20μL (10umol / L) of SEQ ID NO.1 and SEQ ID NO.2 primers (Beijing Aoke Biological Company)

[0121] 5ml deionized double distilled water (ddH2O),

[0122] 100 μL 10×BsrI restriction endonuclease reaction buffer (New England Biolabs, USA)

[0123] 35 μL (10U / μL) restriction endonuclease BsrI (New England Biolabs, USA)

[0124] 2. How to use

[0125] 1. Extract the subject's genomic DNA by conventional methods;

[0126] 2. PCR reaction:

[0127] Table 6

[0128] Reactive components

stock solution concentration

Volume (uL)

Final concentration

Genomic DNA

Upstream primer (SEQ ID NO.1)

Downstream pri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses use of 15 genetic polymorphic sites of growth differentiation factor in predicting hypertensive secondary left ventricular hypertrophy, and belongs to the field of medical molecular biological technology. The present invention is superior in that it determines the action of GDF15 genetic polymorphism in hypertensive secondary left ventricular hypertrophy, and utilizes relevant SNP for providing medicine targets in treating hypertensive secondary left ventricular hypertrophy and providing guide in individualized diagnosis and prognosis.

Description

technical field [0001] The invention relates to the application of growth differentiation factor 15 gene polymorphic sites in predicting left ventricular hypertrophy secondary to hypertension, and belongs to the field of medical molecular biology. Background technique [0002] Left ventricular hypertrophy (LVH) is the main direct complication of hypertension. According to the survey, among the 4270 hypertensive patients in rural areas of our country, those with heart hypertrophy accounted for 42.8%. Left ventricular hypertrophy is recognized as a precursor to heart failure and an important independent risk factor for heart failure, stroke, coronary heart disease and sudden death. Studies have shown that left ventricular hypertrophy can easily lead to blood stasis in the heart, atrial fibrillation and other arrhythmias, promote thrombosis, and increase the risk of ischemic stroke by 2.5 times. In addition, left ventricular hypertrophy increases the overall incidence of card...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68
Inventor 惠汝太王晓建杨旭孙凯陈敬洲宋晓东王曙霞王虎张禅那
Owner FUWAI HOSPITAL OF CARDIOVASCULAR DESEASE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com